Physician profile
John Park
NPI 1417503830
$620.33
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9.49 · 2020: $28.82 · 2021: $182 · 2022: $312 · 2023: $58.22 · 2024: $29.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $129.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.03 | 2022 | |
| Lilly USA, LLC | $59.56 | 2021-2023 | Jardiance, Emgality |
| Alkermes, INC. | $57.97 | 2021-2023 | Vivitrol |
| Integra Lifesciences Corporation | $49.84 | 2022 | |
| Daiichi Sankyo INC. | $40.83 | 2021 | |
| Pacira Therapeutics, INC. | $36.31 | 2021 | |
| Stryker Corporation | $29.73 | 2024 | Spinejack |
| Novo Nordisk INC | $25.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.61 | 2023 | Gattex |
| Myovant Sciences INC. | $19.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.38 | 2022 | |
| Glaxosmithkline, LLC. | $14.50 | 2021 | |
| Sanofi Pasteur INC. | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.